Inspra Approved For First-Line CHF; Pfizer Expects Most Use Will Be Add-On

Pfizer's Inspra is expected to be primarily used as add-on therapy for congestive heart failure despite FDA approval of the selective aldosterone blocker for first-line use

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet